Drug Trial Radar · NCT02107872
Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
Last checked: Nov 20, 2026Latest source record: Sep 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Apr 2014
Primary completion
Sep 2015
Study completion Sep 2015
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Apr 8, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to assess the safety, tolerability, pharmacokinetic (PK), immunogenicity, and pharmacodynamic (PD) effects of REGN1500 in patients with a metabolic disorder.
Conditions
- Metabolic Disorders
Interventions
REGN1500Drug
placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- SafetyTime frame: visit 1 to day 183 (EOS)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Daytona Beach, Florida
Site not named
Evansville, Indiana
Site not named
Dallas, Texas
Site not named
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.